Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

637
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
637
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

357
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
357
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

259
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
259
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

776
Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
776
Genome-wide Association Studies-GWAS01:11

Genome-wide Association Studies-GWAS

15.1K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
15.1K
Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

277
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
277

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Analysis of risk factors for acute kidney injury following reoperative cardiac surgery].

Zhonghua wai ke za zhi [Chinese journal of surgery]·2026
Same author

[Expert consensus on the clinical application of endometrial ablation].

Zhonghua fu chan ke za zhi·2025
Same author

Haematotoxicity of Craniospinal Radiochemotherapy for Metastatic Paediatric High-Grade Glioma.

Clinical oncology (Royal College of Radiologists (Great Britain))·2025
Same author

[Analysis of factors associated with false-positive results and optimal positivity thresholds of quantitative fecal immunochemical test in colorectal cancer screening].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[The practice and exploration on the continuous medical service in children's hospital].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same author

[Whole-process, sequential and proactive nutritional management strategies for cow's milk protein allergy in infants and young children].

Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]·2025
Same journal

Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.

European review for medical and pharmacological sciences·2026
Same journal

Intracoronary stem cell transplant in ischemic heart disease: a meta-analysis of randomized trials.

European review for medical and pharmacological sciences·2026
Same journal

From models to medicine: advanced preclinical systems and AI enabling RNA therapeutics in triple-negative breast cancer.

European review for medical and pharmacological sciences·2026
Same journal

Association of serum asprosin levels with obesity indices and metabolic parameters in adults.

European review for medical and pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Dec 19, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.1K

Correlation between MRAS gene polymorphism and atherosclerosis.

Z-Y Wu1, Z-G Wu, H-M Qi

  • 1Department of Cardiology, Jiangxi Provincial People's Hospital, Jiangxi Provincial Cardiovascular Disease Institute, Nanchang, China. nadinewzg@163.com.

European Review for Medical and Pharmacological Sciences
|June 5, 2020
PubMed
Summary
This summary is machine-generated.

Muscle RAS oncogene homolog (MRAS) gene polymorphisms, specifically rs9818870 (genotype TT) and rs3755751, are linked to an increased risk of atherosclerosis (AS). These findings suggest MRAS gene variations play a role in AS development.

More Related Videos

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.3K

Related Experiment Videos

Last Updated: Dec 19, 2025

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment
07:26

High-resolution Melting PCR for Complement Receptor 1 Length Polymorphism Genotyping: An Innovative Tool for Alzheimer's Disease Gene Susceptibility Assessment

Published on: July 18, 2017

12.1K
A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
07:00

A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

Published on: April 1, 2019

10.3K
Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus
06:43

Quantitative Analysis and Characterization of Atherosclerotic Lesions in the Murine Aortic Sinus

Published on: December 7, 2013

14.3K

Area of Science:

  • Genetics
  • Cardiovascular Disease
  • Molecular Biology

Background:

  • Atherosclerosis (AS) is a major cause of cardiovascular disease.
  • Genetic factors are known to influence AS susceptibility.
  • The role of muscle RAS oncogene homolog (MRAS) gene in AS pathogenesis requires further investigation.

Purpose of the Study:

  • To investigate the association between specific muscle RAS oncogene homolog (MRAS) gene polymorphisms and the risk of developing atherosclerosis (AS).
  • To analyze the correlation of MRAS gene loci rs9818870 and rs3755751 with AS onset risk.

Main Methods:

  • Case-control study involving 135 AS patients and 150 healthy controls.
  • DNA extraction from venous blood samples.
  • Analysis of MRAS gene loci rs9818870 and rs3755751 using the multiplex SNaPshot method.

Main Results:

  • No significant difference in allele frequencies between AS patients and controls for the studied loci.
  • Genotype TT at rs9818870 was associated with a significantly higher risk of AS (p=0.041).
  • The recessive model of rs9818870 and the dominant model of rs3755751 showed correlations with AS in subgroups with coronary heart disease and hypertension, respectively.

Conclusions:

  • The muscle RAS oncogene homolog (MRAS) gene is correlated with the onset of atherosclerosis (AS) to a certain degree.
  • Specific polymorphisms in the MRAS gene may contribute to AS susceptibility, particularly in individuals with comorbidities like coronary heart disease and hypertension.